Alan C. Herman

Ajinomoto Althea, Inc. provides biopharmaceutical contract development and manufacturing services to biotechnology and pharmaceutical companies worldwide. It offers development services in the areas of process development, protein formulation technology, analytical development and validation, and regulatory support. The company was founded by Magda Marquet and Francois Ferre in 1998 and is headquartered in San Diego, CA.

Windrose Medical Properties Trust operated real estate investment trusts. It provided business planning, design, development, finance and management services to healthcare systems, physician groups, and third party medical property owners. Its portfolio includes medical office buildings, outpatient treatment, diagnostic centers, and ambulatory surgery centers. The company was founded in 2002 and was headquartered in Indianapolis, IN.

The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc.